EyePoint Pharmaceuticals Toekomstige groei

Future criteriumcontroles 2/6

De winst van EyePoint Pharmaceuticals zal naar verwachting dalen met 1% per jaar, terwijl de jaarlijkse omzet naar verwachting zal groeien met 44.8% per jaar. De winst per aandeel zal naar verwachting groeien met 5% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -81.8% zijn.

Belangrijke informatie

-1.0%

Groei van de winst

5.0%

Groei van de winst per aandeel

Pharmaceuticals winstgroei	23.9%
Inkomstengroei	44.8%
Toekomstig rendement op eigen vermogen	-81.8%
Dekking van analisten	Good
Laatst bijgewerkt	18 Dec 2024

Recente toekomstige groei-updates

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Aug 09

Recent updates

EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) 29% Share Price Plunge Could Signal Some Risk

Dec 13

EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity

Nov 14

Revenues Not Telling The Story For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) After Shares Rise 52%

Oct 29

EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Intrinsic Value Is Potentially 38% Above Its Share Price

Sep 13

EyePoint Pharmaceuticals - After A Tough 2024 To Date, Is It Time To 'Buy The Dip' (Rating Upgrade)

Aug 29

These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat

Aug 15

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Aug 09

Some Confidence Is Lacking In EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) As Shares Slide 27%

Jun 19

EyePoint's Setback In NPDR Does Not Bode Well For DME (Rating Downgrade)

May 06

More Unpleasant Surprises Could Be In Store For EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Shares After Tumbling 26%

Mar 31

EyePoint Pharmaceuticals: Innovating Eye Treatment, Yet A 'Hold' At This Time

Feb 20

Subdued Growth No Barrier To EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) With Shares Advancing 41%

Feb 05

Is EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Trading At A 28% Discount?

Jan 29

Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 194% But Growth Is Lacking

Dec 18

These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat

Dec 13

Calculating The Fair Value Of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

May 14

Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 84% But Growth Is Lacking

Apr 17

EyePoint Pharmaceuticals: Key Player In The Long-Acting Wet AMD Space

Aug 30

Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?

Jul 16

EyePoint Pharma announces 12-month phase 1 data for its treatment for eye disorder wAMD

Jul 15

Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?

Mar 06

Winst- en omzetgroeiprognoses

NasdaqGM:EYPT - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	8	-217	-152	-190	8
12/31/2025	15	-178	-137	-158	11
12/31/2024	42	-120	-130	-106	11
9/30/2024	46	-104	-118	-113	N/A
6/30/2024	50	-87	-94	-90	N/A
3/31/2024	50	-79	-17	-12	N/A
12/31/2023	46	-71	-2	2	N/A
9/30/2023	43	-100	9	12	N/A
6/30/2023	37	-106	12	14	N/A
3/31/2023	40	-102	-64	-62	N/A
12/31/2022	41	-102	-67	-65	N/A
9/30/2022	42	-78	-71	-69	N/A
6/30/2022	41	-77	-64	-64	N/A
3/31/2022	39	-67	-55	-55	N/A
12/31/2021	37	-58	-50	-50	N/A
9/30/2021	33	-54	-28	-28	N/A
6/30/2021	39	-42	-19	-19	N/A
3/31/2021	34	-44	-14	-13	N/A
12/31/2020	34	-45	-15	-14	N/A
9/30/2020	36	-40	-32	-32	N/A
6/30/2020	23	-52	-48	-48	N/A
3/31/2020	26	-51	-60	-60	N/A
12/31/2019	20	-57	-57	-57	N/A
9/30/2019	14	-58	-56	-56	N/A
6/30/2019	12	-75	-53	-53	N/A
3/31/2019	6	-98	-42	-42	N/A
12/31/2018	5	-86	-34	-33	N/A
9/30/2018	3	-80	-28	-28	N/A
6/30/2018	3	-53	N/A	-22	N/A
3/31/2018	3	-25	N/A	-20	N/A
12/31/2017	3	-23	N/A	-20	N/A
9/30/2017	8	-17	N/A	-20	N/A
6/30/2017	8	-18	N/A	-20	N/A
3/31/2017	7	-19	N/A	-20	N/A
12/31/2016	7	-19	N/A	-20	N/A
9/30/2016	1	-24	N/A	-18	N/A
6/30/2016	2	-22	N/A	-16	N/A
3/31/2016	2	-20	N/A	-15	N/A
12/31/2015	2	-20	N/A	-15	N/A
9/30/2015	2	-19	N/A	10	N/A
6/30/2015	27	6	N/A	10	N/A
3/31/2015	26	8	N/A	11	N/A
12/31/2014	28	10	N/A	13	N/A
9/30/2014	28	11	N/A	-11	N/A
6/30/2014	3	-13	N/A	-11	N/A
3/31/2014	4	-13	N/A	-11	N/A
12/31/2013	2	-14	N/A	-11	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat EYPT de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat EYPT de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat EYPT de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van EYPT ( 44.8% per jaar) zal naar verwachting sneller groeien dan de markt US ( 9.1% per jaar).

Hoge groei-inkomsten: De omzet van EYPT ( 44.8% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat EYPT binnen 3 jaar verliesgevend zal zijn.

Ontdek groeibedrijven

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2024/12/22 00:48
Aandelenkoers aan het einde van de dag	2024/12/20 00:00
Inkomsten	2024/09/30
Jaarlijkse inkomsten	2023/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige regelgevingsformulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Lees hier meer.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op .

Bronnen van analisten

EyePoint Pharmaceuticals, Inc. wordt gevolgd door 19 analisten. 11 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Colleen Kusy	Baird
Andrew D'Silva	B. Riley Securities, Inc.
Jennifer Kim	Cantor Fitzgerald & Co.

EyePoint Pharmaceuticals Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Consensus revenue estimates fall by 18%

Price target increased by 28% to US$39.29

Consensus revenue estimates increase by 19%

Consensus revenue estimates increase by 13%

EyePoint Pharmaceuticals, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2022

Recent updates

EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) 29% Share Price Plunge Could Signal Some Risk

Eyepoint Pharmaceuticals, Inc. Announces First Patient Dosed in Second Global Phase 3 Lucia Clinical Trial of DURAVYU for the Treatment of Wet Age-Related Macular Degeneration

EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity

EyePoint Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $140.000003 million.

EyePoint Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $140.000003 million.

Revenues Not Telling The Story For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) After Shares Rise 52%

EyePoint Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

EyePoint Pharmaceuticals, Inc. Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU for Diabetic Macular Edema

Eyepoint Pharmaceuticals, Inc. Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of Durasert for the Treatment of Wet Age-Related Macular Degeneration

EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Intrinsic Value Is Potentially 38% Above Its Share Price

EyePoint Pharmaceuticals, Inc. Announces Board Changes

EyePoint Pharmaceuticals - After A Tough 2024 To Date, Is It Time To 'Buy The Dip' (Rating Upgrade)

These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

EyePoint Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

EyePoint Pharmaceuticals, Inc. Highlights Duravuyu Clinical and Regulatory Progress and Pipeline Innovation At R&D Day 2024

Some Confidence Is Lacking In EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) As Shares Slide 27%

New major risk - Revenue and earnings growth

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Revenue and earnings growth

EyePoint's Setback In NPDR Does Not Bode Well For DME (Rating Downgrade)

Consensus revenue estimates fall by 18%

New major risk - Shareholder dilution

EyePoint Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

EyePoint Pharmaceuticals, Inc. Expands Scientific Advisory Board

More Unpleasant Surprises Could Be In Store For EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Shares After Tumbling 26%

Full year 2023 earnings: EPS and revenues exceed analyst expectations

EyePoint Pharmaceuticals, Inc. Announces Management Changes

EyePoint Pharmaceuticals: Innovating Eye Treatment, Yet A 'Hold' At This Time

Executive Vice-Chairman exercised options and sold US$430k worth of stock

Subdued Growth No Barrier To EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) With Shares Advancing 41%

EyePoint Pharmaceuticals, Inc. Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular Degeneration

Senior VP & Chief Medical Officer exercised options and sold US$621k worth of stock

Is EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Trading At A 28% Discount?

Executive Vice-Chairman recently sold US$874k worth of stock

Senior VP & Chief Medical Officer notifies of intention to sell stock

Executive Vice-Chairman exercised options and sold US$470k worth of stock

EyePoint Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2 Verona Clinical Trial of Eyp-1901 for the Treatment of Diabetic Macular Edema

Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 194% But Growth Is Lacking

These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat

Executive Vice-Chairman recently sold US$415k worth of stock

EyePoint Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $200.000002 million.

Senior VP & Chief Medical Officer notifies of intention to sell stock

EyePoint Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $200.000002 million.

Price target increased by 28% to US$39.29

EyePoint Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $175 million.

EyePoint Pharmaceuticals, Inc. Announces Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet Amd Achieving All Primary and Secondary Endpoints

New major risk - Revenue and earnings growth

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

EyePoint Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 01, 2023

EyePoint Pharmaceuticals, Inc. Announces Executive Changes

EyePoint Pharmaceuticals, Inc. Reports Positive Masked Safety Update for Lead Product Candidate Eyp-1901 in Ongoing Pavia and Davio 2 Phase 2 Clinical Trials as of September 1, 2023

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

EyePoint Pharmaceuticals, Inc. Announces Interim Masked Safety Data and Patient Baseline Characteristics for EYP-1901

EyePoint Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Consensus revenue estimates increase by 19%

Eyepoint Pharmaceuticals, Inc. Announces Chief Executive Officer Changes

Eyepoint Pharmaceuticals Completes Enrollment in Phase 2 Pavia Clinical Trial of Eyp-1901 in Non-Proliferative Diabetic Retinopathy

Consensus revenue estimates increase by 13%

Alimera Sciences, Inc. entered into an agreement to acquire YUTIQ® from EyePoint Pharmaceuticals, Inc. for $82.5 million.

Calculating The Fair Value Of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 84% But Growth Is Lacking

Full year 2022 earnings: EPS misses analyst expectations

EyePoint Pharmaceuticals, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2022

Eyepoint Pharmaceuticals Promotes Jay S. Duker, M.D. to President and Chief Operating Officer

High number of new directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind